Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-01-07
2008-11-11
Campell, Bruce (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
07449190
ABSTRACT:
The present invention relates to assays for the identification of compounds that inhibit assembly of NP, VP35, and VP24, or inhibit the glycosylation of NP, required for nucleocapsid formation, for use as anti-viral agents. The invention also relates to assays for the identification of compounds that block glycosylation of proteins having a glycosylation domain that is substantially homologous to a glycosylation domain of NP required for polymerization. The invention further relates to pseudoparticles for presentation of antigens or antigenic epitopes for immunogenic or vaccination purposes.
REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 6200577 (2001-03-01), McLaughlan et al.
patent: 2004/0057967 (2004-03-01), Bavari et al.
patent: WO 95/32310 (1995-11-01), None
patent: WO 00/09158 (2000-02-01), None
Reed et al., Status and challenges of filovirus vaccines, Vaccine 25 (2007) 1923-1934.
Warfield et al., Filovirus-like particles as vaccines and discovery tools, Expert Rev Vaccines, 2005, 4(3):429-440.
Aoki, K. et al. 1999 “Efficient generation of recombinant adenoviral vectors by cre-lox recombination in vitro.”Mol. Med. 5:224-231.
Becker, S. et al. 1994 “The nucleoprotein of marburg virus is phosphorylated.”J. Gen. Virol. 75:809-818.
Becker, S. et al. 1998 “Interactions of marburg virus nucleocapsid proteins.”Virology249:406-417.
Chen, C. et al. 1987 “High-efficiency transformation of mammalian cells by plasmid DNA.”Mol. Cell. Biol. 7:2745-2752.
Delchambre, M. et al. 1989 “The gag precursor of simian immunodeficiency virus assembles into virus-like particles.”EMBO J. 8:2653-2660.
Dessen, A. et al. 2000 “Crystal structure of the matrix protein VP40 from ebola virus.”EMBO J. 19:4228-4236.
Elliott, L.H. et al. 1985 “Descriptive analysis of ebola virus proteins.”Virology147:169-176.
Feldmann, H. et al. 1992 “Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle.”Virus Res. 24:1-19.
Feldmann, H. et al. 1996 “Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages.”J. Virol. 70:2208-2214.
Feldmann, H. et al. 1996 “Marburg and ebola viruses.”Adv. Virus Res. 47:1-52.
Feldmann, H. et al. 1999 “Classification, structure, and replication of filoviruses.”Curr. Top. Microbiol. Immunol. 235:1-21.
Feldmann, H. et al. 2001 “Biosynthesis and role of filoviral glycoproteins.”J. Gen. Virol. 82:2839-2848.
Friborg, J. Jr. et al. 1999 “p53 inhibition by the LANA protein of KSHV protects against cell death.”Nature402:889-894.
Garoff, H. et al 1998. “Virus maturation by budding.”Microbiol. Molec. Biol. Rev. 62:1171-1190.
Geisbert, T.W. et al. 1992 “Association of ebola-related reston virus particles and antigen with tissue lesions of monkeys imported to the United States.”J. Compar. Pathol. 106:137-152.
Geisbert, T.W. et al. 1995 “Differentiation in filoviruses by electron microscopy.”Virus Res. 39:129-150.
Gheysen, D. et al. 1989 “Assembly and release of HIV-1 precursor Pr55gagvirus-like particles from recombinant baculovirus-infected insect cells.”Cell59:103-112.
Han, I. et al. 1997 “Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility.”Mol. Cell. Biol. 17:2550-2558.
Hanover, J.A. 2001 “Glycan-dependent signaling: O-linked N-acetylglucosamine.”FASEB J. 15:1865-1876.
Horikami, S.M. et al. 1992 “Complexes of sendai virus NP-P and P-L proteins are required for defective interfering particle genome replication in vitro.”J. Virol. 66:4901-4908.
Huang, Y. et al. 2001 “Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.”J. Virol. 75:4947-4951.
Huang, Y. et al. 2002 “The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein.”Mol. Cell10:307-316.
Huber, M. et al. 1991 “Measles virus phosphoprotein retains the nucleocapsid protein in the cytoplasm.”Virology185:299-308.
Jasenosky, L.D. et al. 2001 “Ebola virus VP40-induced particle formation and association with the lipid bilayer.”J. Virol. 75:5205-5214.
Kiley, M.P. et al. 1988 “Physicochemical properties of marburg virus: evidence for three distinct virus strains and their relationship to ebola virus.”J. Gen. Virol. 69:1956-1967.
Le Guenno, B. et al. 1995 “Isolation and partial characterisation of a new strain of ebola virus.”Lancet345:1271-1274.
Lowe, J.B. 2001 “Glycosylation, immunity, and autoimmunity.”Cell104:809-812.
Luo, L. et al. 1994 “Mapping of functional domains for HIV-2 gag assembly into virus-like particles.”Virology205:496-502.
Martin-Serrano, J. et al. 2001 “HIV-1 and ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress.”Nat. Med. 7:1313-1319.
Maruyama, T. et al. 1999 “Ebola virus can be effectively neutralized by antibody produced in natural human infection.”J. Virol. 73:6024-6030.
Moody, A.M. et al. 2001 “Developmentally regulated glycosylation of the CD8αβ coreceptor stalk modulates ligand binding.”Cell107:501-512.
Muhlberger, E. et al. 1998 “Three of the four nucleocapsid proteins of marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of marburg virus-specific monocistronic minigenomes.”J. Virol. 72:8756-8764.
Muhlberger, E. et al. 1999 “Comparison of the transcription and replication strategies of marburg virus and ebola virus by using artificial replication systems.”J. Virol. 73:2333-2342.
Roquemore, E.P. et al. 1994 “Detection of O-linked N-acetylglucosamine (O-GlcNAc) on cytoplasmic and nuclear proteins.”Meth. Enzymol. 230:443-460.
Ruigrok, R.W. et al. 2000 “Structural characterization and membrane binding properties of the matrix protein VP40 of ebola virus.”J. Mol. Biol. 300:103-112.
Sanchez, A. et al. 1993 “Sequence analysis of the ebola virus genome: organization, genetic elements, and comparison with the genome of marburg virus.”Virus Res. 29:215-240.
Schnittler, H-J. et al. 1993 “Replication of marburg virus in human endothelial cells: a possible mechanism for the development of viral hemorrhagic disease.”J. Clin. Invest. 91:1301-1309.
Schwemmle, M. et al. 1998 “Interactions of the borna disease virus P, N, and X proteins and their functional implications.”J. Biol. Chem. 273:9007-9012.
Smith, A.J. et al. 1993 “Requirements for incorporation of Pr160gag-polfrom human immunodeficiency virus type 1 into virus-like particles.”J. Virol. 67:2266-2275.
Starr, C.M. et al. 1990 “Glycosylation of nuclear pore protein p62. Reticulocyte lysate catalyzes O-linked N-acetylglucosamine addition in vitro.”J. Biol. Chem. 265:6868-6873.
Sullivan, N.J. et al. 2000 “Development of a preventive vaccine for ebola virus infection in primates.”Nature408:605-609.
Timmins, J. et al. 2001 “Vesicular release of ebola virus matrix protein VP40.”Virology283:1-6.
Tooze, J. et al. 1988 “Site of addition of N-Acetyl-galactosamine to the E1 glycoprotein of mouse hepatitis virus-A59.”J. Cell Biol. 106:1475-1487.
Volchkov, V.E. et al. 2001 “Recovery of infectious ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity.”Science291:1965-1969.
Wells, L. et al. 2001 “Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc.”Science291:2376-2378.
Wills, J.W. et al. 1989 “Creation and expression of myristylated forms of rous sarcoma virus gag protein in mam
Huang Yue
Nabel Gary
Campell Bruce
Kinsey White Nicole
Knobbe Martens Olson & Bear LLP
The United States of America as represented by the Department of
LandOfFree
Assays for assembly of Ebola virus nucleocapsids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assays for assembly of Ebola virus nucleocapsids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays for assembly of Ebola virus nucleocapsids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4025191